drugset / Trial / NCT00822861
Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum eosinophils and the airway responses during an allergen challenge at different dose levels.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPI ASM8 | Oligonucleotide (other) | 1 mg | Inhaled |
| Subject | TPI ASM8 | Oligonucleotide (other) | 2 mg | Inhaled |
| Subject | TPI ASM8 | Oligonucleotide (other) | 4 mg | Inhaled |
| Subject | TPI ASM8 | Oligonucleotide (other) | 8 mg | Inhaled |